On Tuesday, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was -2.21% drop from the session before settling in for the closing price of $19.02. A 52-week range for ARWR has been $17.05 – $39.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 21.04%. When this article was written, the company’s average yearly earnings per share was at -137.85%. With a float of $116.03 million, this company’s outstanding shares have now reached $124.31 million.
Let’s determine the extent of company efficiency that accounts for 525 employees. In terms of profitability, gross margin is 11.29%, operating margin of -2785.05%, and the pretax margin is -2792.41%.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arrowhead Pharmaceuticals Inc stocks. The insider ownership of Arrowhead Pharmaceuticals Inc is 6.66%, while institutional ownership is 76.63%. The most recent insider transaction that took place on Jul 02 ’24, was worth 237,480. In this transaction Chief Commercial Officer of this company sold 9,394 shares at a rate of $25.28, taking the stock ownership to the 127,107 shares. Before that another transaction happened on May 02 ’24, when Company’s Director sold 1,799 for $23.31, making the entire transaction worth $41,935. This insider now owns 30,205 shares in total.
Arrowhead Pharmaceuticals Inc (ARWR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -137.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.33% during the next five years compared to -24.19% drop over the previous five years of trading.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
You can see what Arrowhead Pharmaceuticals Inc (ARWR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 117.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.65, a number that is poised to hit -0.97 in the next quarter and is forecasted to reach -4.36 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Looking closely at Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR), its last 5-days average volume was 1.27 million, which is a jump from its year-to-date volume of 1.2 million. As of the previous 9 days, the stock’s Stochastic %D was 9.95%. Additionally, its Average True Range was 0.93.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 11.60%, which indicates a significant increase from 9.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.12% in the past 14 days, which was higher than the 50.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.00, while its 200-day Moving Average is $24.78. However, in the short run, Arrowhead Pharmaceuticals Inc’s stock first resistance to watch stands at $18.91. Second resistance stands at $19.22. The third major resistance level sits at $19.45. If the price goes on to break the first support level at $18.37, it is likely to go to the next support level at $18.14. Should the price break the second support level, the third support level stands at $17.83.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
There are 124,315K outstanding shares of the company, which has a market capitalization of 2.31 billion. As of now, sales total 240,740 K while income totals -205,280 K. Its latest quarter income was 0 K while its last quarter net income were -125,300 K.
